Clinical Trial

Evaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced Diabetes

Enrolling by Invitation Phase 4
View on ClinicalTrials.gov →
Summary
Glucocorticoids are commonly used in the treatment of autoimmune, inflammatory, and neoplastic diseases. Despite their therapeutic efficacy, they are associated with significant metabolic side effects. In the proposed research, the aim is to assess the metabolic efficacy and safety of fixed-ratio combination therapy (basal insulin + GLP-1 receptor agonist) compared to standard insulin therapy in patients with SID. In a selected group of patients, a randomised clinical trial would be conducted to assess the potential benefits of GLP-1 receptor agonists in the management of SID.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-04.
Trial Details
NCT Number NCT07117240
Lead Sponsor Medical University of Warsaw
Conditions Steroid-Induced Diabetes, Steroid-Induced Hyperglycemia, Diabetes
Enrollment 100 participants
Start Date 2025-07-10
Primary Completion 2028-02-09 (estimated)
Study Completion 2028-07-10 (estimated)
Updated on ClinicalTrials.gov 2025-09-19